Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00812487 · ClinicalTrials.gov registry record · Phase 1
Glycemic Control and Variability for Congestive Heart Failure Exacerbation
A Phase 1 study, sponsored by Kathleen Dungan.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00812487: Completed Phase 1 study, sponsored by Kathleen Dungan.
NCT00812487 is a Phase 1 study that has completed, run by Kathleen Dungan. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00812487, a Phase 1 study, has completed, sponsored by Kathleen Dungan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
High glucose as well as fluctuations (rapid swings) in blood glucose can contribute to severe hospital complications and even death.
Interventions
- DRUG Intravenous insulin
- DRUG Subcutaneous insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00812487
The ClinicalTrials.gov registry entry for NCT00812487 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kathleen Dungan, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intravenous insulin is the first listed.
NCT00812487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00812487 about?
NCT00812487 is a clinical study titled "Glycemic Control and Variability for Congestive Heart Failure Exacerbation". High glucose as well as fluctuations (rapid swings) in blood glucose can contribute to severe hospital complications and even death.
What is the current status of trial NCT00812487?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2009-01. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00812487?
The interventions under investigation include: Intravenous insulin (DRUG), Subcutaneous insulin (DRUG).
Who is sponsoring clinical trial NCT00812487?
This trial is sponsored by Kathleen Dungan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.